Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Income from Continuing Operations came in at 36602000.0 in Q1 2026, up 11.22% YoY from 32910666.35 in Q1 2025, and down 66.48% on a QoQ basis from 21986000.0 in Q4 2025.
Travere Therapeutics (TVTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Income from Continuing Operations data on file, last reported at 36602000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 11.22% year-over-year to 36602000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 45637000.0 (up 79.8% YoY) and the FY2025 annual result came in at 50261000.0, up 84.32% from the prior year.
- Income from Continuing Operations declined to 36602000.0 in Q1 2026, from 21986000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 25706000.0 in Q3 2025 to a low of 135958000.0 in Q1 2024.
- A 5-year average of 65605529.41 and a median of 80023000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 135.87% — and 2025, when it jumped 146.95%.
- Tracing TVTX's Income from Continuing Operations over 5 years: stood at 85636000.0 in 2022, then decreased by 3.46% to 88596000.0 in 2023, then surged by 31.97% to 60268000.0 in 2024, then surged by 63.52% to 21986000.0 in 2025, then plunged by 66.48% to 36602000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 36602000.0 (Q1 2026), 21986000.0 (Q4 2025), and 25706000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -34.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.80 Mn |
| Mar 31, 2026 | -36.60 Mn |
| Dec 31, 2025 | -21.99 Mn |
| Sep 30, 2025 | 25.71 Mn |
| Jun 30, 2025 | -12.76 Mn |
| Mar 31, 2025 | -41.23 Mn |
| Dec 31, 2024 | -60.27 Mn |
| Sep 30, 2024 | -54.75 Mn |
| Jun 30, 2024 | -69.65 Mn |
| Mar 31, 2024 | -135.96 Mn |
| Dec 31, 2023 | -88.60 Mn |
| Sep 30, 2023 | -89.24 Mn |
| Jun 30, 2023 | -101.93 Mn |
| Mar 31, 2023 | -96.56 Mn |
| Dec 31, 2022 | -85.64 Mn |
| Sep 30, 2022 | -84.06 Mn |
| Jun 30, 2022 | -80.02 Mn |
| Mar 31, 2022 | -81.75 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |